During breast cancer radiotherapy, nearly all patients will experience radiodermatitis. Study objectives were as follows: (1) systematically review the literature on radiodermatitis and breast cancer; (2) summarize and describe patient-rated radiodermatitis measures; (3) determine whether consensus exists regarding subjective radiodermatitis measurement; and (4) provide recommendations for future research. PubMed and CINAHL were searched from their inception through August 2009. Study inclusion and exclusion criteria were: full abstract available, manuscript in English, focused on radiodermatitis resulting from breast cancer radiotherapy, and described a patient-rated empirical assessment of radiodermatitis. Three reviewers examined abstracts, and decisions about inclusion were reached by consensus. Twenty-two of 237 mutually identified studies met selection criteria. Using a standardized abstraction form, 3 authors independently extracted relevant information. Results indicated that (1) only 9% of the studies reviewed included a patient-rated measure; (2) generally, extant scales are very brief and focus almost exclusively on physical reactions, and (3) there is no ''gold standard'' measure of patient-rated radiodermatitis at this time. We conclude that significantly more research is needed to determine the best (most valid, reliable, sensitive, comprehensive) measure(s) to evaluate the experience of radiodermatitis from the patient's perspective, and that further scale development efforts are needed.
R adiotherapy is a key element of curative breast cancer treatment, and it has been estimated that 45% of all breast cancer patients receive radiotherapy. 1 During the course of breast cancer radiotherapy, most patients (74% to 100%) will experience radiodermatitis, also referred to as skin toxicity. [2] [3] [4] [5] The physical manifestations of radiodermatitis can range from faint erythema (redness, warmth, rash-like appearance), to dry desquamation (dryness, itching, peeling), to moist desquama-tion (moist, oozing, tender, redness and exposure of the dermis) and necrosis. [6] [7] [8] [9] After the conclusion of radiotherapy, patients may experience cutaneous fibrosis, which involves changes in skin texture, skin retraction, discomfort, telangiectasia, pain, and itching. 10 Radiodermatitis not only affects breast skin, but also the breast cancer patient herself. Qualitative research and review articles have suggested that radiodermatitis may be experienced by patients as itching, sensitivity, pain, numbness, tenderness, warmth, tingling, throbbing, tightness, heaviness, and burning, 3, 11 and that skin pain may be associated with fatigue, body image disturbance, sleep problems, and emotional distress. 12, 13 Such qualitative data suggest that to understand the impact of radiodermatitis on quality of life, it is critical to assess not only the occurrence of skin reactions, but also patients' subjective experience of such reactions. 14 However, there has been a paucity of research focused on the patient's experience of radiodermatitis, including the degree to which radiodermatitis impairs quality of life (QOL), 15 causes pain, 16 or causes distress. 15 Indeed, with regard to radiodermatitis, ''rarely have studies considered patient comfort of primary importance'' (p. E9). 12 Overall, the effects of radiation-related skin reactions on QOL are ''largely absent in the literature'' (p. E11). 12 This lack of attention to the patient's subjective experience is inconsistent with the emphasis placed on QOL by major health organizations (World Health Organization, 17 Institute of Medicine 18, 19 ), as well as with the more widespread recognition of the need to assess patient-rated symptoms in addition to observer-rated measures. 14, [20] [21] [22] The lack of research on the patient's subjective experience of radiodermatitis is problematic for at least 4 reasons. First, 2 people with the same observer-rated level of radiodermatitis (eg, with the same Radiation Therapy Oncology Group score 6 ) may have very different subjective experiences. As Schmuth et al 23 have noted (p. 987), ''Clinical judgment and bioengineering techniques alone cannot reflect the potential impact of a skin condition on patients' lives.'' Second, if not inquired about, important symptoms (eg, pain, impaired body image, impaired functioning) may go unrecognized and unmanaged, potentially leading to impaired patient QOL, poor treatment satisfaction, and social constraints 24 in the doctor-patient relationship. Third, breast cancer patients cannot make fully informed treatment decisions (ie, whether or not to undergo radiotherapy) without data on how the treatment may affect their QOL. 14 Fourth, if patients are not provided with accurate information about radiotherapy sideeffects, it can inhibit their ability to cope with, understand, and interpret their treatment experience; increase feelings of uncertainty; and hinder problem solving. 3 It has been suggested that research on radiodermatitis has been hampered by the absence of a widely accepted and psychometrically sound scale to assess skin reactions. 4, 11 Although a number of commonly used and well-accepted observer-rated methods of evaluating radiodermatitis exist, 6, 25 as well as more technological approaches (eg, reflectance spectroscopy), the patient's experiences of symptoms and QOL have been given less attention. 4 In 1999, Noble-Adams 11 reviewed the literature on assessment of radiation-induced skin reactions in general (not focused on breast), and found that the most common assessment method at the time for radiodermatitis was physician-rated visual observation scales, and that there existed no scale at the time that could be used to assess the subjective symptoms of radiotherapy-induced skin reactions. 26 The goal of the present article was to: (1) provide an up-to-date systematic review of the literature on radiodermatitis and breast cancer to learn which patient-rated instruments have been used to assess subjective radiodermatitis; (2) summarize and describe patient-rated radiodermatitis measures to inform future research efforts; (3) determine whether consensus exists regarding subjective radiodermatitis measurement; and (4) to provide recommendations for the use of current instruments as well as for future scale development in this area.
METHOD
The QUORUM checklist 27 guided the conduct and reporting of this systematic review.
Data Sources and Search Strategy
Two electronic databases, PubMed and CINAHL, were searched from their respective inceptions through August 19, 2009.
For PubMed, the search terms were ''Radiodermatitis'' (Mesh) AND [''Breast Neoplasms'' (Mesh) OR breast]. Limits placed on the search required articles to be about human beings and in English. This search yielded 202 abstracts and/or titles.
For CINAHL, the search terms were (''breast neoplasms'' or ''breast'') AND radiodermatitis. The only limit placed on the search was that the article had to be in English. This search yielded 35 abstracts and/or titles.
Study Selection Strategy
The abstracts and/or titles of all articles identified by electronic searches (237 in total) were carefully screened by 3 of the authors to determine whether they met the following inclusion criteria: (a) full abstract available online; (b) manuscript written in English; (c) focused on or included breast cancer patients; (d) focused on radiotherapy for the treatment of breast cancer (eg, not other types of radiation); (e) focused on radiodermatitis resulting from radiotherapy; (f) described a patient-rated empirical assessment of radiodermatitis (eg, excluded qualitative studies and other-rated measures); and (g) the study was not a duplicate (ie, if an article was cited in both PubMed and CINAHL, it was only used once).
Subsequent to abstract review, 46 manuscripts were obtained and read in full, independently by 3 coauthors, each of whom completed a standardized form assessing the inclusion criteria. These coauthors then met together to review these 46 manuscripts. On the basis of consensus review by these reviewers, 22 of those 46 mutually identified studies met selection criteria and were included in the meta-analysis. Reasons for exclusion are identified in Figure 1 -QUORUM Flowchart. 27 
Data Extraction and Study Characteristics
For each of the 22 papers included in the review, relevant data were extracted independently by 3 of the authors, using a standardized worksheet. Specifically, the standardized worksheet was used to collect the following information: authors, publication year, sample size, type of study (eg, intervention study, descriptive study, scale development study), type of radiation received, scale name (if provided), number of scale items related to radiodermatitis, constructs measured, item rating method, and frequency of administration. Any discrepancies were discussed among the authors with reference to the original manuscript until consensus was reached. It should be noted that: (a) if a given paper reported both subjective and objective data (eg, patient-rated and physicianrated), we focused only on the assessment items specifically identified as patient-rated or subjective; (b) if a given paper reported on both quantitative and qualitative data, we only report on the quantitative data. Although both are critical pieces of information, the goal of the present review was to survey empirical measures of subjective radiodermatitis which could be used in future research; (c) if a given paper had a mixed cancer sample, we only report on the breast cancer patients; and (d) only questions or questionnaires pertaining to skin reactions and related QOL were included. Other types of questions (eg, opinions about interventions, adverse effects related to creams under investigation, skin products used) are not reported on in the present review. Again, this decision was made in the interest of compiling questions or measures which could be used in clinical settings and across radiodermatitis studies (eg, intervention studies, longitudinal studies, etc) in breast cancer. Table 1 presents the chief characteristics of each study and scale. The papers were published between 1979 and 2009. Sample size ranged from 2 to 331; of the 22 identified studies, 12 had fewer than 50 breast cancer patients, 2 had 50 to 100, 3 had 100 to 200 patients, and 5 had more than 200 breast cancer patients. Three of the studies did not report the specific type of radiation patients received; the rest involved external beam radiation. None was specifically focused on alternate forms of radiation treatment (eg, accelerated hypofractionated radiation regimens, partial breast irradiation, etc.). The majority of the studies (86%) were intervention studies (testing the effectiveness of various creams, homeopathic treatments, mechanical massage, behavioral strategies). Only 1 4 was specifically focused on the development and validation of a radiodermatitis scale. Most of the studies focused on acute toxicity. Only 5 of 22 papers reported ethnicity data on participants, and in all those 5, more than 85% of the sample was white.
RESULTS

Description of Trial, Sample, and Intervention Characteristics
Data Synthesis and Description of Scale Characteristics
The primary finding is that only 9% of the abstracts reviewed included any patient-rated measure. In other words, 91% of the studies of radiodermatitis in breast cancer patients did not ask patients about their symptom experience. The papers which did meet inclusion criteria discussed 28 measures (some of which were single item measures). The depth of the description of the measures varied greatly between manuscripts. In some manuscripts measures are described in great detail, whereas in others the description is limited to 1 sentence, making data synthesis difficult. However, based on our consensus reading of the manuscripts, the results are as follows.
Tremendous heterogeneity was noted both in terms of scales used and items assessed. For example, none of the previously developed, psychometrically sound scales included in these papers (eg, Skin Toxicity Assessment Tool, Spitzer QOL, Radiation-Induced Skin Reaction Assessment Scale, European Organization for Research and Treatment of Cancer C-30 general module or BR-23 breast cancer-specific module, Skindex, SF-36, or Dermatology Life Quality index) was used more than once. Furthermore, the only scales that did appear to be used more than once were pain visual analog scales (k = 4) and symptom diary cards (k = 3). However, because only 1 of the 4 pain visual analog scales reported their numerical and verbal anchors, we cannot be sure that these 4 visual analogue scales are identical. In general, the data suggest that there currently exists no clear consensus in the field in terms of measuring patient-rated radiodermatitis.
Heterogeneity was also noted in terms of specific items assessed (see Table 1 , ''Constructs Measured''). This suggests that there is no well-accepted definition of the construct of ''radiodermatitis'' from the patients' perspective. Every study is, in effect, measuring its own version of radiodermatitis. For 1 study it may mean cosmesis, for another pain, for another, more comprehensive effects on QOL. This diversity further makes it difficult to compare across studies, and to build a knowledge base in this area.
Yet despite the heterogeneity, the following trends became apparent: (1) Most of the 28 scales were extremely brief---79% were between 1 and 5 items. (2) The most commonly asked items were erythema or redness, desquamation or peeling, burning, itching, and pain. (3) Regarding dimensions of QOL assessed, more than half (61%) focused solely on physical well-being. A smaller subset of studies looked at both physical well-being and functional well-being (25%). However, other domains of QOL were more rarely examined, and only 11% took a more comprehensive approach (ie, 3 or more domains of QOL assessed) to examining radiodermatitis effects on multiple domains of QOL. 15, 23, 46 (4) Clear empirical data describing scale properties (eg, reliability, validity, time to complete, reading level) was largely absent.
DISCUSSION
This systematic review of the literature on patient-rated measures of radiodermatitis in breast cancer radiotherapy provides an important snapshot of the current state of research in this area, and revealed at least 5 important areas for future growth.
Our primary finding was that of the 237 abstracts and/or titles reviewed, only 9% actually asked breast cancer patients about their experience of radiodermatitis. In other words, in studies of radiodermatitis, an extremely common treatment side effect, the patient's experience, perceptions, suffering, and evaluations have generally been ignored by the breast radiotherapy research literature. These results are quite similar to findings by Noble-Adams from a decade ago, 11 and disappointingly suggest that little progress has been made in this area. It seems impossible to comprehensively evaluate the success or failure of any new radiotherapy technique, or any new symptom control intervention, without assessing whether patients themselves are more comfortable, are more satisfied with their appearance, feel less pain, are more satisfied with the texture of the breast, sleep better, or are more satisfied with treatment. Of course we recognize that clinically, radiotherapy treatment teams discuss these issues extensively with patients. However, if these factors are not regularly assessed in research enterprises, treatment guidelines may be decided on without true consideration of the patient experience and without empirical data. In consequence, it is our recommendation that all future prospective research on radiotherapy-induced skin changes in breast cancer patients include at least one patient-rated measure. This will ensure that QOL is not ignored in this population.
Second, we noted that among those studies which did measure patient-rated radiodermatitis, there was no clear agreement on which scale to use and little consistency regarding items assessed. The high variability in assessment approaches is problematic, and makes it difficult to develop norms or compare results across studies. 46 Moreover, the variability suggests a lack of consensus not merely in terms of measurement, but also in terms of a clear definition of the construct of patient-rated radiodermatitis. Our own qualitative work 13 suggests that to comprehensively account for patient experiences, a patient-rated skin toxicity measure should at minimum include items about: (a) nociceptive or tactile effects (eg, pain or discomfort, burning or heat, itching, tingling, pulling and heaviness, skin texture); (b) body image and satisfaction with skin color changes and skin texture; (c) emotional reactions; (d) functional impairment (eg, clothing or bra changes, sleep impairment, work performance); and (e) satisfaction with radiotherapy. Our general recommendation is that more work (both quantitative and qualitative) be conducted to develop an operational definition of radiodermatitis that accurately represents patients' experiences and voices. Third, we found that the scales in use were generally quite brief and limited in scope, and focused almost exclusively on 1 particular aspect of QOL---physical well-being. To address this limitation, we suggest that future research regularly address multiple dimensions of QOL. Among the scales already in use, the most comprehensive are the Skindex, European Organization for Research and Treatment of Cancer, SF-36, and Dermatology Life Quality Index. However, Wells et al 15 raised some concerns about the sensitivity of the Dermatology Life Quality Index, and more work is needed to determine the appropriateness of each of these measures in the breast cancer radiotherapy setting. More broadly, we recommend that significantly more research be conducted to develop a new, comprehensive, radiodermatitis scale for breast cancer patients, which is informed by qualitative research as well as expert opinions. It should be noted that we recognize that skin toxicity scales may exist, or may be used more frequently, in radiotherapy populations other than breast. However, without sufficient testing and validation in breast samples, it is unclear whether they are appropriate for this population.
Fourth, we strongly recommend that more attention (ie, better reporting) be given to descriptions of the scales, including description of supporting literature, wording or anchors, number of items, and psychometric properties. Without such knowledge, it is difficult to interpret the quality of the data collected, 14 and difficult to make informed decisions about using the scale in future research. Consequently, we recommend that psychometric properties of the scales be included in research reports on patient-rated radiodermatitis, and that in the future, research focus on the development and use of psychometrically reliable and valid scales.
Fifth, of those studies which did report ethnicity, samples were predominantly white. To determine the appropriateness of these measures across ethnic groups, future research should include more diverse samples of patients.
Of course, like any study, the present review has its limitations. First, the search strategy was focused. The MESH term ''radiodermatitis'' was the descriptor used to search for radiotherapy related skin toxicity. However, different search terms could lead to different results. As a check on our search strategy, we examined 2 recent reviews in the area. 47, 48 Of the 38 studies included in these reviews, only 3 additional studies [49] [50] [51] would have met our inclusion criteria, and none of these 3 papers included a scale which was not already reported on in Table 1 . More specifically, one used a visual analog scale and the other 2 rated itching or pain as none, mild, moderate, or severe. Thus, the information provided by these additional manuscripts does not change the conclusions of the present review, that the field lacks a ''gold standard'' patientrated self-report measure of skin changes associated with breast cancer radiotherapy. Second, the present review included 2 databases---PubMed and CINAHL, and was limited to published manuscripts in English. It is possible that additional relevant papers exist outside of the present sample of papers. Future work may include more languages, include unpublished manuscripts, and use a wider variety of search terms to confirm the generalizability of the present conclusions. Third, we chose not to conduct quality appraisals of the included studies, as is suggested in the QUORUM 27 guidelines. We chose not to do this because we were focused on the quality of the measures, rather than the overall quality of the studies in which a measure was used. We view study quality and measure quality as separate issues. Future research may rate both study and measure quality to be used as covariates in meta-analytic approaches.
In conclusion, this review suggests that although some important efforts have been made to assess breast cancer patients' experiences of radiodermatitis, the literature in this area is relatively underdeveloped compared with the literature on other cancer-related symptoms, side-effects, and QOL. 20, 21, [52] [53] [54] With regard to radiodermatitis, it has been stated that ''Accurate assessment of both the subjective symptoms and the observable signs of these reactions is a prerequisite in enabling an understanding of the phenomenon and planning appropriate care. Until a holistic, valid and reliable tool is developed the concept cannot be fully examined'' (p. 1140). 11 It is our hope that the present review will spur development of such a tool, and focus attention on the patient experience.
